|Day Low/High||75.01 / 75.87|
|52 Wk Low/High||51.82 / 77.12|
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.
- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC
AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of...
Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Bristol-Myers Squibb Company (NYSE:BMY) announced today the commercial launch of the ORENCIA ClickJect TM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis...
Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
Jim Cramer is impressed by Johnson & Johnson's continual growth.
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
Bristol-Myers Squibb Company (NYSE:BMY) announced today U.S.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Doug Kass shares his thoughts on the condition of the global fixed-income markets.
Jim Cramer talks about the post-Brexit world, and how it's now all about the earnings as the jobs report recedes in the distance.
The world didn't end two weeks ago, Cramer says, so everyone should just calm down and tune out the pundits.
Brexit wasn't the cataclysmic event many pundits wailed about, and while there is still uncertainty, the market is showing its resilience.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.
Bristol-Myers (BMY) announced today that it has acquired Swedish-based Cormorant Pharmaceuticals for $520 million.
Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based...
Cramer says Wynn is fantastic but he's avoiding Valeant.
When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd.
The eventual negative implications of Brexit could be greater for health care companies that have sizable exposure to Europe.